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Objective: The onset of symptomatic peripheral arterial disease at a young age (prema-
ture PAD) has been associated with rapid progression, bypass graft failure, and amputa-
tion. This study was performed to document the incidence of these complications and
to determine the risk factors for poor outcome in patients with premature PAD.
Methods: This study was designed as a prospective longitudinal analysis, with patients
who were ambulatory or hospitalized at a single vascular referral institution. The sub-
jects were 51 white men with onset of PAD symptoms before the age of 45 years (mean
age of onset, 41 ± 0.5 years) and represented consecutive patients who were seen at the
vascular surgery service during a 4-year period. Thirty of the study subjects (58%) were
recruited during the first 2 years. The main outcome measures were number and type of
lower extremity revascularization procedures or amputations that were necessitated dur-
ing the follow-up period.
Results: During a mean follow-up period of 73 ± 6 months, 15 patients (29%) had PAD
that remained stable without interventions and 15 (29%) had PAD that remained stable
for a mean of 76 ± 13 months after a single intervention. Twenty-one patients (41%)
required multiple operations or major amputations. In a comparison of the 30 PAD
patients whose conditions were stable with or without a single intervention with the 21
PAD patients who required multiple interventions (REDO), there were no differences in
smoking, hypertension, diabetes, or dyslipidemias. The REDO group had a younger
mean age at the onset of symptoms (39 ± 1 years vs 43 ± 2 years; P < .001). At entry, the
REDO patients had a higher prevalence of infrainguinal or multilevel disease (57% vs
20%; P = .03), a lower mean ankle brachial index (0.44 ± 0.04 vs 0.56 ± 0.03; P = .02),
and more frequent tissue loss (24% vs 0; P = .005). The REDO patients had a higher
mean lipoprotein (a) level than did the patients with stable conditions (51 ± 11 mg/dL
vs 27 ± 5 mg/dL; P = .03), but there were no significant differences in the mean plasma
homocysteine levels (19 ± 2 m mol/L vs 16 ± 1 m mol/L) or in the proportion of patients
with hypercoagulable states (33% vs 30%). The only predictive variables that were select-
ed with stepwise logistic regression analysis were age at onset (P < .002; odds ratio, 1.4;
95% confidence interval, 1.11 to 1.81) and ankle brachial index of less than 0.5 (P < .008;
odds ratio, 6.4; 95% confidence interval, 1.5 to 27.3).
Conclusion: Although 60% of the white men with premature PAD who were referred to a
vascular surgery service had conditions that appeared to remain stable, these data show
that approximately 40% of the patients will require multiple interventions because of dis-
ease progression or bypass graft failure. Clinical indicators, not serum markers, are pre-
dictors of poor outcome in patients with premature PAD. The results of this study suggest
that patients with onset of PAD before the age of 43 years who have objective evidence of
advanced disease are predisposed to multiple interventions. (J Vasc Surg 1999;30:436-45.)
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The onset of symptomatic peripheral arterial dis-
ease before the age of 50 years (premature PAD) has
been associated with an extremely poor prognosis,
but it is uncertain how many young patients are 
predisposed to a poor outcome. The published data 
are conflicting. Although numerous retrospective
study results have suggested that the vast majority of 
individuals with premature PAD are prone to disease 
progression,1-3 bypass graft failure,2-5 and early
death,1,2,6,7 there appear to be subsets of young
patients whose conditions may remain stable for long
periods after intervention. For example, several
groups have reported superior bypass graft patency
rates in patients with premature PAD located primar-
ily in the aortoiliac segment.6-10 In direct contradic-
tion, other investigators have reported that young
patients with aortoiliac disease have bypass graft fail-
ure and amputation rates that are equal to or worse
than those of young patients with infrainguinal dis-
ease or with disease in both locations.3,5,11 Numerous
other clinical conditions that are associated with poor
outcomes have been examined. Retrospective analysis
results have suggested the following as possible risk
factors for progression in unselected populations with
premature PAD: continued cigarette smoking,8 dia-
betes mellitus,2 location of disease,3 small aortic diam-
eter,5 and hypercoagulable states.11,12 However, these
data have been directly refuted by other investiga-
tors.2,9,14,15 Thus, the proportion of individuals with
premature PAD who can be expected to have disease
progression or poor outcomes after intervention
remains unknown and the risk factors for progression
remain undefined.
We previously reported a prospective analysis of
risk factors for the development of premature PAD
in white men who were referred to a vascular surgery
service.15 In a comparison of control subjects who
were matched for age and conventional risk factors,
the patients with premature PAD had higher plasma
levels of lipoprotein (a) (Lp[a]). No other clinical
indicators or serum markers were identified with
multivariate analysis, which confirmed that elevated
Lp(a) levels represent the primary independent risk
factor for the development of premature PAD. The
patients with premature PAD who were originally
entered into this study have now been followed
prospectively for a mean of more than 5 years, which
has afforded the opportunity to determine late out-
comes. The purposes of this study were: (1) to
define the proportion of patients who required mul-
tiple interventions for complications of premature
PAD, and (2) to examine clinical indicators and
serum markers as risk factors for poor outcome
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among the cohorts. On the basis of our previous
results, we hypothesized that the measured plasma
levels of Lp(a) would prove to be the most impor-
tant predictor of late outcome in these patients.
METHODS
Referral population. This study was conducted
at the Dallas Department of Veterans Affairs Medical
Center, a regional medical center that serves more
than 465,000 military veterans from 37 counties in
north Texas and two counties in Oklahoma. The
Center includes a 250-bed acute care hospital and 45
hospital-based outpatient clinics. Outside referrals are
generated from nine community-based outpatient
clinics that serve the north Texas area and from a wide
variety of physician specialists and general practition-
ers who work outside the Department of Veterans
Affairs medical system. Approximately 1500 patients
with a variety of vascular problems are seen each year
in the Vascular Surgery Clinic. Some of the patients
are referred for evaluation of advanced symptoms of
lower extremity ischemia and others are referred for
screening for suspected PAD. 
Subjects. The study subjects represented consec-
utive white men who were seen at the vascular surgery
service with symptoms of lower extremity atheroscle-
rotic occlusive disease that began at age 45 years or
younger. All the patients were seen at the vascular
surgery service through the usual referral patterns. No
attempt was made to solicit patients from physicians
on the basis of entry criteria. A total of 53 white men
with premature PAD were seen by our service during
the study period. Of these patients, 48 were previous-
ly reported.15 Two of the original 50 study patients
were lost to follow-up examination within 1 year of
entry into the study, and three additional patients
underwent evaluation in the 2 months after the orig-
inal study terminated. The original study evaluated
the strength of Lp(a) as a risk factor for premature
PAD, and the inclusion criteria are documented in the
original report.15 After entry into the study, all 51
study subjects were followed in the vascular surgery
clinic indefinitely. Scheduled appointments were
made at least on a yearly basis, and most subjects were
seen more frequently. Living patients who missed
scheduled appointments were contacted and inter-
viewed by telephone. All the study subjects gave
informed consent according to a protocol that was
approved by the Institutional Review Board of the
medical center.
Analysis of vascular occlusive disease. As pre-
viously described,15 all the subjects were studied to
determine the location and extent of atherosclerotic
occlusive disease. Each participant underwent evalu-
ation for the presence of atherosclerotic risk factors
and for the degree of incapacitation from lower
extremity occlusive disease (claudication, rest pain,
tissue loss). Detailed histories were obtained regard-
ing the presence of coronary artery disease (CAD)
and cerebrovascular disease. Patients without CAD
indicators underwent exercise treadmill tests or
adenosine thallium scintigraphy. All the study partic-
ipants underwent complete evaluation of the cere-
bral and lower extremity circulations with standard-
ized noninvasive tests as previously detailed.15
Determination of disease progression. The
main focus of this study was to determine the num-
ber of patients who had multiple bypass graft failures
or who required major amputations. Therefore, dis-
ease progression was defined according to the number
of interventions or major amputations that were
necessitated during the follow-up period. The num-
ber, type, and location of lower extremity interven-
tions were recorded for each patient. Changes in the
degree of incapacitation (eg, development of rest
pain or tissue loss) or in ankle brachial index (ABI)
were also noted. Disease progression in the coronary
circulation was defined as new onset angina, myocar-
dial infarctions, or coronary revascularizations that
occurred during the follow-up period. Serial carotid
duplex scanning was not performed on all the study
patients. Therefore, disease progression in the cerebral
circulation was defined as new transient ischemic
attacks, strokes, or carotid endarterectomies that
occurred during the follow-up period.
Laboratory assays. All the study participants
underwent phlebotomy at the time of entry into the
study for measurement of plasma Lp(a) concentra-
tion, total plasma homocysteine levels, and coagula-
tion assays to detect hypercoagulable states. Assays
for the following hypercoagulable states were per-
formed: antiphospholipid antibodies and deficien-
cies in antithrombin III, protein C, and protein S.
Collection and laboratory methods have been
detailed previously.15
Statistics. Statistical analysis was performed
with the SAS 6.12 Computer Package (SAS
Institute, Inc, Cary, NC). Continuous data are
expressed as mean ± standard error of the mean.
Univariate comparisons of risk factors and other
dichotomous variables between study groups were
performed with c 2 test. Continuous measures were
evaluated with the Student t test. Life-table analysis
was used to estimate survival and intervention-free
intervals with the Kaplan-Meier method.16 Logistic
regression was used to provide P values and odds
ratios for the continuous measures, with the consid-
eration of progression of PAD as the outcome mea-
sure. Stepwise logistic regression was provided for
the variable selection of the risk factors associated
with the progression of PAD. New variables were
created by performing a median split on the contin-
uous variables and resulted in the following thresh-
old values: age at onset, 43 years; ABI, 0.5; toe pres-
sure (TP), 55 mm Hg; Lp(a), 20.5 mg/dL; and
homocysteine, 15.6 m mol/L. These binary variables
then were entered into the multivariate logistic
model. In addition to the median split, Lp(a) levels
were entered into the model as dichotomous vari-
ables with thresholds of 20 mg/dL, 30 mg/dL, and
40 mg/dL. The following variables were considered
in the stepwise logistic regression analysis: smoking,
hypertension, diabetes mellitus, dyslipidemia, age at
onset, tissue loss, location of PAD, ABI, TP, plasma
Lp(a) level, presence of hypercoagulable state, and
plasma homocysteine level.
RESULTS
Study subjects. The mean age of the study
patients was 46 ± 0.5 years, and the mean age at
onset of symptoms was 41 ± 0.5 years. The mean
time between reported onset of symptoms and entry
into the study was 4.4 ± 0.4 years. Demographics
and atherosclerotic risk factors of the study subjects
are shown in Table I. All 51 study subjects had clau-
dication symptoms of at least 1 year’s duration
before entry into the study. The interval between
onset of symptoms and study entry was 1 to 2 years
in 12 subjects (24%), between 2 and 5 years in 23
subjects (45%), and more than 5 years in 16 subjects
(31%). At entry, 18 subjects (35%) had had rest pain
develop and five subjects (10%) with rest pain also
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Table I. Demographics and atherosclerotic risk
factors among the study participants
PAD subjects (n = 51)
Mean age at entry (years) 46 ± 0.5
Mean age at onset of symptoms (years) 41 ± 0.5
History of smoking 50 (98%)
Hypertension 18 (35%)
Diabetes mellitus 11 (22%)
Dyslipidemia* 18 (35%)
CAD 33 (65%)
Cerebrovascular disease 9 (18%)
Carotid stenosis ‡ 50% 15 (30%)
PAD, Peripheral arterial disease; CAD, coronary artery disease.
*Serum cholesterol > 240 mg/dL or serum triglycerides > 300
mg/dL.
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had evidence of tissue loss. Lower extremity lesions
were found predominantly in the aortoiliac segment
in 33 subjects (65%), in the femoropopliteal seg-
ment in nine subjects (18%), and in both segments
in nine subjects (18%). The mean lowest ABI among
the study subjects was 0.51 ± 0.02, and the mean
lowest systolic toe pressure was 52 ± 5 mm Hg.
Thirty-three study patients (65%) had a history
of CAD. This diagnosis was made on the basis of a
history of coronary revascularization in 14 subjects,
with coronary catheterization in 15 subjects, with
electrocardiography (Q waves) in two subjects, and
with adenosine thallium scintigraphy (fixed defect)
in two subjects. Six study patients had CAD exclud-
ed on the basis of normal coronary catheterizations
(n = 3) or adenosine thallium scans (n = 3). Twelve
other subjects were believed to have normal exercise
test results. Although all 12 subjects had claudica-
tion symptoms, each was able to achieve an adequate
work load during exercise to exclude clinically sig-
nificant CAD. Nine patients (18%) had a history of
cerebrovascular disease, five of whom had under-
gone previous carotid endarterectomies. Eight
patients (16%) had a history of cerebrovascular
symptoms (three transient ischemic attacks, five
strokes), and one had undergone carotid endarterec-
tomy for an advanced, asymptomatic internal carotid
stenosis. Twenty-six subjects (51%) had evidence of
carotid artery stenoses with duplex scanning:
stenoses measured 1% to 49% in 11 patients, 50% to
79% in seven patients, and 80% to 99% in two
patients. Six subjects had internal carotid occlusions.
Outcome. The mean duration of follow-up
examination for the 51 study subjects was 73 ± 6
months (median, 63 months; interquartile range, 40
to 100 months). During this time, 15 subjects (29%)
had conditions that remained stable and did not
necessitate interventions to treat claudication symp-
toms (Fig 1). There were no appreciable changes in
the degree of incapacitation or in the objective vascu-
lar tests among the 15 patients. With life-table analy-
sis, the 5-year intervention-free survival rate was 36%
(Fig 2). Thirty-six patients (71%) underwent revascu-
larization procedures. The mean time interval
between onset of symptoms and first intervention was
53 ± 6 months. Initial revascularization procedures
occurred at other institutions before entry into the
study in four patients, within 1 month of entry in 14
patients, between 1 month and 1 year of entry in six
patients, and more than 1 year after entry in 12
patients. The indication for initial revascularization
was severe, progressive claudication in nine subjects
and limb-threatening ischemia in 27 subjects. The
patients who underwent intervention for claudication
had work-limiting or lifestyle-limiting symptoms and
had failed attempts at conservative management for at
least 6 months. Fifteen of the 36 patients (41%)
underwent a single intervention for severe claudica-
tion (n = 5) or limb-threatening ischemia (n = 10)
and had conditions that remained stable for a mean of
76 ± 13 months after intervention. Twenty-one other
patients (41%) underwent a mean of 4 ± 0.4 inter-
ventions. The indication for initial intervention in this
subgroup was severe claudication in four patients and
limb-threatening ischemia in 17 patients. All 21 sub-
jects had suffered from limb-threatening ischemia at
the time of subsequent procedures; none was believed
to be a candidate for conservative management. After
Fig 1. Outcome of 51 patients with premature PAD.
Stable, Proportion of patients who did not undergo revas-
cularization procedures; one intervention, proportion of
patients whose conditions remained clinically stable for
long periods after single revascularization procedure; mul-
tiple interventions, proportion of patients who required
two or more revascularizations or major amputations.
Fig 2. Kaplan-Meier curve shows intervention-free sur-
vival rate among all 51 study patients.
the first intervention in these 21 patients, the mean
time to a second revascularization procedure or
amputation was 20 ± 5 months. Fourteen of these
patients had progressive disease in adjacent beds or in
the opposite leg and required infrainguinal bypass
grafting after aortic procedures (n = 9), more distal
bypass grafting after femoropopliteal procedures (n =
3), or contralateral bypass grafting (n = 2). Seven
additional patients had disease in the same vascular
bed and required aortofemoral bypass grafting after
failed balloon angioplasty (n = 5) or graft revisions (n
= 2). After the second intervention, two patients had
not undergone further operations, but three had
required major leg amputations. Eight patients have
undergone third attempts at revascularization, two of
which have come to major amputation. Eight other
patients have undergone four or more procedures.
The mean time from onset of symptoms to first
intervention was 53 ± 7 months in the 15 patients
who underwent one intervention, which was not
different as compared with 53 ± 9 months in the 21
patients who underwent multiple interventions. The
mean duration of follow-up examination after study
entry was 66.3 ± 9 months in the subjects who did
not undergo interventions, which was not signifi-
cantly different as compared with 76 ± 13 months in
the subjects who underwent one intervention or
with 76.7 ± 9 months among subjects who required
multiple interventions (P = .74).
During the follow-up period, 15 of the 51
patients (29%) had progression of CAD (six myocar-
dial infarcations, six coronary revascularizations, two
progressions of disease with coronary catheteriza-
tion, and one new onset angina) and 11 patients
(21%) had new cerebrovascular symptoms. Seven
patients (14%) died: four of complications after
myocardial infarctions, two from sepsis after ampu-
tations, and one of unknown causes. With life-table
analysis, the 5-year survival rate was 92% (Fig 3).
Examination of risk factors for poor out-
come. For the purposes of evaluating possible risk
factors predictive of which patients were likely to
undergo multiple interventions, the 15 patients who
had stable symptoms were grouped together with
the 15 patients whose conditions had remained sta-
ble for long periods of time after a single interven-
tion. Comparisons between these 30 patients (STA-
BLE) and the 21 patients who underwent multiple
operations (REDO) were made to determine the
prevalence of risk factors for poor outcome in the
two groups. Demographic and atherosclerotic risk
factor comparisons are shown in Table II. The
REDO patients had a younger mean age at the onset
of PAD symptoms, but there were no differences in
the prevalence of smoking, hypertension, diabetes
mellitus, or dyslipidemias between the two groups.
Comparisons between clinical indicators are shown
in Table III. The patients in the STABLE group
were more likely to have disease confined to the aor-
toiliac segment, and the patients in the REDO
group were more likely to have infrainguinal or mul-
tilevel disease (P = .025). Although the location of
disease was significantly different between the two
groups, the site of initial revascularization had little
bearing on the tendency for progression. Fourteen
of the 26 subjects (54%) in either group who under-
went aortoiliac revascularization required subse-
quent procedures, which was not significantly differ-
ent as compared with the seven of nine (78%) who
underwent infrainguinal reconstruction. However,
the site of initial revascularization was somewhat
predictive of a future need for amputation: major
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Table II. Comparison of demographics and risk
factors between the two study groups
REDO STABLE P value
No. of patients 21 30
Age at onset (years) 39 ± 0.5 43 ± 2 <.001
Smoking .11
Continued 19 (90%) 23 (77%)
Stopped 1 (5%) 7 (23%)
Never 1 (5%) —
Hypertension 12 (57%) 16 (53%) NS
Diabetes mellitus 5 (24%) 6 (20%) NS
Dyslipidemia 8 (38%) 10 (33%) NS
Mean no. of risks 2.7 ± 0.3 2.2 ± 0.2 NS
REDO, Patients who underwent multiple operations; STABLE,
patients who either did not require intervention or whose condi-
tions had remained stable for long periods of time after a single
intervention; NS, not significant.
Fig 3. Kaplan-Meier curve shows survival rate among 51
study patients.
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amputations were eventually necessitated in five of
the 26 patients (19%) in either group who under-
went initial aortoiliac revascularization as compared
with five of nine patients (56%) who underwent
infrainguinal reconstruction (P < .04).
The severity of symptoms at the time of entry
into the study were predictive of a tendency towards
progression, as were noninvasive test results (Table
III). The REDO group had twice the proportion of
patients with limb-threatening ischemia at the study
outset. Both the mean lowest recorded ABI and the
mean lowest recorded systolic toe pressure were sig-
nificantly lower in the REDO versus the STABLE
patients.
Neither of the two study groups was more likely
to have progression of disease in other vascular beds
(Table III). Seven of the patients who had progres-
sion of CAD were in the REDO group, which was
not significantly different as compared with the eight
in the STABLE group. Among the patients who had
new cerebrovascular symptoms during the follow-up
period, six were in the REDO group and five were in
the STABLE group (no significant difference).
Serum markers were variably predictive of group
assignment. Group comparisons are shown in Table
IV. The patients in the REDO group had a higher
mean Lp(a) concentration as compared with the
patients in the STABLE group (P = .03). A higher
proportion of REDO patients had plasma Lp(a) lev-
els that were more than 30 mg/dL, but the differ-
ence between the two groups was of borderline sig-
nificance (P = .05). There was a trend toward high-
er serum homocysteine levels in the REDO patients,
but the difference did not achieve statistical signifi-
cance (P = .12). There were no significant differ-
ences in the number of patients with identified
hypercoagulable states between the two groups, nor
was there a difference in the mean number of hyper-
coagulable states.
Multivariate analysis. Stepwise logistic regres-
sion analysis considered independent predictive vari-
ables of REDO versus STABLE subjects. The only
predictive variables selected with the multivariate
model were age at onset (P < .002; odds ratio, 1.42;
95% confidence interval, 1.11 to 1.81) and ABI of
less than 0.5 (P < .008; odds ratio, 6.44; 95% confi-
dence interval, 1.5 to 27.3).
DISCUSSION
In 1996, we reported that elevated levels of
serum Lp(a) represent the only independent risk fac-
tor for the development of premature PAD.14 No
other serum markers or clinical indicators were sig-
nificantly associated with premature PAD by means
of multivariate analysis. The present results show that
clinical indicators, not serum markers, are risk factors
for progression of premature PAD, which was
defined as a need for multiple interventions. In par-
ticular, elevated Lp(a) levels are not predictive of
poor outcome, which disproves the hypothesis of this
study. The clinical markers that were associated with
multiple interventions in this study suggest that
patients with earlier disease onset and those with
more extensive disease with objective criteria are
prone to poor outcomes. This should not be surpris-
ing because patients with onset of symptoms at an
Table IV. Comparison of serum markers between
the two groups
REDO STABLE P value
Lp(a) (mg/dL) 51 ± 11 27 ± 5 .032
Lp(a), >30 mg/dL 12 (57%) 9 (30%) .053
No. with hypercoagulable 7 (33%) 9 (30%) NS
states
Mean no. with hypercoag- 0.38 ± 0.13 0.33 ± 0.1 NS
ulable states
Homocysteine (m mol/L) 19 ± 2 16 ± 1 .12
REDO, Patients who underwent multiple operations; STABLE,
patients who either did not require intervention or whose condi-
tions had remained stable for long periods of time after a single
intervention; Lp(a), lipoprotein (a); NS, not significant.
Table III. Comparison of clinical indicators between
the two groups
REDO STABLE P value
Location of disease .025
Aortoiliac 9 (43%) 24 (80%)
Infrainguinal 6 (29%) 3 (10%)
Multilevel 6 (29%) 3 (10%)
Severity of symptoms at study entry .019
Claudication only 11 (52%) 22 (74%)
Rest pain 5 (24%) 8 (26%)
Tissue loss 5 (24%) —
Lowest ABI 0.44 ± 0.04 0.56 ± 0.03 .016
Lowest toe pressure 37 ± 7 63 ± 6 .008
(mm Hg)
CAD NS
At entry 12 (57%) 21 (70%)
Progression 7 (33%) 8 (27%)
Cerebrovascular disease NS
At entry 5 (25%) 4 (13%)
Progression 6 (29%) 5 (17%)
Deaths 4 (19%) 3 (10%) NS
REDO, Patients who underwent multiple operations; STABLE,
patients who either did not require intervention or whose condi-
tions had remained stable for long periods of time after a single
intervention; ABI, ankle brachial index; CAD, coronary artery
disease; NS, not significant.
earlier age are likely to have a more aggressive form
of atherosclerosis, regardless of the underlying cause.
The present data indicate that the odds of progres-
sion on the basis of age of onset is 1.42 per year of
age. This means, for example, that an individual
whose onset of PAD symptoms occurred at 39 years
is 2.1 times more likely to require multiple interven-
tions as compared with an individual whose PAD
symptoms began at age 44 years. Patients with lower
ABI at the outset probably have more diffuse athero-
sclerosis, which may also reflect a more aggressive
form of atherosclerosis. Among the numerous clini-
cal variables examined, multivariate analysis results
selected ABI of less than 0.5 as the strongest predic-
tor of poor outcome. This probably accounted for
the significant risk with univariate analysis that was
associated with other variables, such as tissue loss,
location of disease, and degree of incapacitation.
The 5-year survival rate of 92% in this study is
higher than that previously reported for patients with
premature PAD. Retrospective study results have
documented 5-year mortality rates ranging from 17%
to 26%.1,2,9,11 This difference most likely reflects the
timing of patient entry. The focus of the previous
studies was on patients who had undergone inter-
ventions for advanced symptoms; in this study, many
patients were entered long before interventions, and
some never underwent interventions at all. Three of
the patients in this study died more than 5 years after
entry into the original study but within 5 years after
an intervention. The 96-month survival rate of 82%
(Fig 3) is in keeping with previous reports. As was
reported in the latter studies, most deaths in this
study were caused by cardiovascular complications.
It is somewhat surprising that the progression of
disease in the lower extremity did not correlate with
the progression in other vascular beds. Some instances
of disease progression may have been missed.
However, both groups would have been at risk for
missed data and it is doubtful that the overall results
would have been affected. The most likely explana-
tion for this seeming disparity is that premature ath-
erosclerosis in the coronary and cerebral circulations
are under the influences of different risk factors for
progression. A strong association has been shown
between elevated levels of Lp(a) and progression of
premature atherosclerosis in the coronary or cerebral
circulations.18,19 An association between elevated
homocysteine levels and progression of disease in
these arterial beds has also been reported.20 In a com-
parison of the results of this study, these data suggest
that peripheral atherosclerosis in young adults is influ-
enced by different risk factors.
The definition of progression in this study was
made on the basis of the number of interventions
rather than on other data, such as worsening symp-
toms or dropping ABI values. We chose this defini-
tion because of the reported tendency for patients
with premature PAD to require multiple interven-
tions or amputations as the result of bypass graft fail-
ure. We concede that multiple interventions repre-
sent a surrogate marker for disease progression. The
precise anatomic documentation of the severity of
progression is not available in all patients. As is the
case with older patients, the indications for inter-
vention were individualized. Some patients under-
went operations to correct lifestyle-limiting claudica-
tion, and others underwent operations for limb
preservation. Nevertheless, three clear clinical pat-
terns emerged during the follow-up period. Approx-
imately 30% of the subjects had stable claudication
symptoms and no changes in objective test results.
Among the 70% of patients who underwent inter-
ventions, there appeared to be a subgroup who had
stable symptoms and objective test results for long
periods after a single intervention. The remainder
required additional procedures within a relatively
short time after the initial intervention. Some vascu-
lar surgeons would have offered revascularization to
a small proportion of our patients who did not
undergo interventions, and others would have rec-
ommended a more conservative course to those who
did undergo revascularizations. Regardless of the
decision to perform an initial operation for relief of
claudication, the STABLE group was clinically sepa-
rable from the REDO group on the basis of the need
for multiple operations in the latter. We concede that
some crossover may have existed between the
groups because it is possible that some of the
patients in the STABLE group will have progression
of lower extremity atherosclerosis in the ensuing
years. However, our data suggest that this will be an
unusual occurrence. Ninety-seven percent of the
STABLE patients have been followed for more than
3 years, and 100% of the patients in the REDO
group required reinterventions within 3 years.
Limitations. Despite the study being a prospec-
tive, long-term analysis of premature PAD, limita-
tions did exist. The first potential limitation is that
the study population was restricted to whites. This is
explained by the inclusion criteria of the original
study, which analyzed Lp(a) levels in these patients.
Because there is a wide variation in Lp(a) lipoprotein
levels among racial subgroups without a corre-
sponding increase in the risk of CAD,21 we exclud-
ed black, Asian, and Hispanic patients from the orig-
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inal analysis. Therefore, the results of this study do
not apply to other racial subgroups.
A second potential limitation is that the nature of
our referral population restricted the focus of the
study to men. Although the present results do not
apply to women, at least one study has documented
similar risk factors for progression in women and
men with premature PAD.2 The proportion of men
and women who had progression of PAD was also
similar. Because many of the variables considered in
this study were not examined in the previous report,
we speculate that age at onset and ABI of less than
0.5 are equally significant risk factors for the progres-
sion of premature PAD among men and women.
A third potential limitation is that this is not a
population-based study. Our study group was select-
ed from consecutive patients who were seen at a vas-
cular surgery service. Therefore, the present conclu-
sions cannot be generalized to all populations of
adults with premature PAD. Our findings are limit-
ed to young white men who were referred to a vas-
cular surgery service at a military veterans medical
center. However, we do not believe that our study
group had a significant referral bias as compared
with other medical centers with similar referral pat-
terns. The patients in this study were referred
through a wide variety of avenues, without regard to
the degree of symptoms. None of our patients was
solicited according to the present inclusion criteria.
These young men represent approximately 4% of our
vascular practice, which is in keeping with the pro-
portions previously described by others.8,11 We
believe that these findings are applicable to large vas-
cular centers with similar referral patterns and
patient demographics.
A fourth limitation relates to the variability in the
degree of symptoms among our subjects. Some of
our subjects had advanced ischemia at the time of
initial presentation, and others had minimal symp-
toms. Therefore, the study subjects do not represent
a true inception cohort. However, there was no dif-
ference in the mean time interval between onset of
claudication symptoms and first intervention among
patients in the two groups who underwent revascu-
larization procedures. Similarly, the mean time inter-
val between the onset of symptoms and the entry
into the study were nearly identical between the two
groups. This suggests that the two groups had a sim-
ilar distribution in the stage of disease progression,
thus minimizing duration of disease as a predictor of
outcome. Our data indicate that other clinical fac-
tors, especially the degree of ischemia at presenta-
tion (ie, study entry), represent the most important
predictors of need for multiple interventions in these
patients. However, because our findings are limited
to a select population, we concede that the propor-
tion of patients in the general population who will
have progression of disease remains unknown.
These results have important implications for
patients with premature PAD. At the present time,
there do not appear to be controllable risk factors for
the progression of disease. The clinical risk factors
identified in this study are mere markers for patients
who are at risk for poor outcome. As such, they may
help to identify patients who should be subjected to
more aggressive follow-up examination, but these
clinical markers cannot be altered to slow the pro-
gression of PAD. Screening for hypercoagulable states
and determination of Lp(a) and homocysteine levels
appears to be of dubious importance in these patients,
and we currently recommend against it. On the other
hand, control of traditional risk factors (smoking,
hyperlipidemia, diabetes mellitus, and hypertension)
are associated with improvement in outcome from
CAD. It follows that the modification of these risk
factors may improve late survival in patients with pre-
mature PAD who are at risk for CAD progression.
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Dr Daniel S. Rush (Johnson City, Tenn). I congratu-
late Dr Valentine on an excellent presentation, and I appre-
ciate the opportunity to review the manuscript and to dis-
cuss his results. The current paper by Dr Valentine and his
colleagues is the latest in a series of thoughtful studies that
seek to discover the reason why so many young patients
with premature peripheral vascular disease respond so
poorly to conventional vascular surgical treatment.
In their earlier work, Dr Valentine demonstrated that
elevated serum lipoprotein (a) is the primary independent
risk factor for the development of premature atherosclero-
sis. Other studies, including our own, propose that these
young patients have a convergence of typical atheroscle-
rotic risk factors, such as smoking, family history, and
hyperlipidemia, especially elevated lipoprotein (a), and
may additionally have certain unique and compounding
risk factors, such as small-caliber arterial segments, hyper-
homocystinemia, hypercoaguable states, and diminished
fibrinolytic activity. Thus, it has been concluded that they
are more likely to have atherosclerosis develop, quicker to
reach a critical stenosis and become symptomatic because
of small vascular segments, more prone to spontaneous
thrombosis, and less likely to lyse whatever clot might
form. In the present study, the authors seek to document
with longitudinal prospective analysis the long-term out-
come of premature peripheral vascular disease and to iden-
tify those risk factors responsible for its progression.
For this purpose, the authors have used a clinical defi-
nition of disease progression related to the number and
success of lower extremity vascular interventions rather
than a pathologic definition. Thus, it is not surprising they
have concluded that clinical indicators, such as younger age
at the onset of symptoms, infrainguinal or multiple level
disease, more severe ischemia, and impending tissue loss,
were predictors of poor outcome and not serum markers,
with the exception, perhaps, again, of lipoprotein (a).
On the surface, this conclusion would seem to contra-
dict other studies, including our own, which indicate an
association between hypercoaguability, specifically a defi-
ciency in protein C activity, and graft failure, multiple pro-
cedures, and amputation in these young patients.
I agree with Dr Valentine’s observations, however,
and I believe that the apparent disparity lies in differences
between the patient population studied and the protocol
under which serum sampling was performed.
In the present study design, all patients were an essen-
tially homogenous population of white males whose
serum markers were tested relatively early in their disease
course at the time of their entry into the study. There were
valid scientific reasons for using this approach because of
possible racial, sexual, and temporal differences in the var-
ious serum markers tested. Our own patients, in contrast,
were a heterogeneous group that included men and
women and blacks and whites, and most patients were
studied much later in their disease course.
Unfortunately, Dr Valentine’s conclusions leave us
with the rather unsettling impression that whatever
occurred in these young patients, whose diseases ultimate-
ly progressed to a poor outcome, seems to have already
been established at the time of their entry into the study.
In this respect, young patients with premature periph-
eral vascular disease would seem to be stratified from the
outset by the distribution of arterial disease, severity of
ischemia, and impending tissue loss, much in the same
manner as typical older patients. I have several questions.
You found that approximately one third of these
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patients had hypercoaguability that was evenly distributed
between the stable patients and those with poor out-
comes. However, from your earlier paper, it appears that
all but three or four of these 16 patients actually had the
antiphospholipid antibody syndrome, which recent
reports indicate may not be as important in the etiology of
arterial thrombosis. Did you perhaps have too few patients
with hypercoaguability caused by natural anticoagulant
deficiencies, such as protein C and antithrombin III, to
reach statistical significance?
Furthermore, other studies have found that hyperco-
aguable states are often acquired rather than innate and
can appear in association with recent ischemic events.
Perhaps some of your patients had borderline normal
serum activities with respect to functional assays of natur-
al anticoagulants during early periods of relative vascular
stability but could become precipitously hypercoaguable,
leading to arterial thrombosis because of reduced serum
levels, altered activation, or inhibition of these serum
markers. Do you think that acquired hypercoaguable
states might have been identified in some of your patients
with poor outcomes if they had been retested during these
later periods of crisis?
Finally, I would like to point out that, unless you have
your own research laboratory, determining these serum
markers can be prohibitively expensive. Do you advocate
that such tests be ordered on these patients?
And finally, we should be actually reassured by Dr
Valentine’s data that many of these young patients, at least
in the early stages of their peripheral vascular disease, are
not at so great a risk of a vascular disaster as we have feared.
Thank you very much.
Dr R. James Valentine. Thank you, Dr Rush, for your
excellent comments and questions. We agree in principle
with you and your group that premature peripheral vascu-
lar disease is probably going to turn out to have a multi-
factorial etiology. Our current theories relate to a combi-
nation of external factors, such as atherosclerotic risk fac-
tors, hypercoaguable states, or elevated lipoprotein (a)
levels, superimposed on a genetic predisposition to early
atherosclerosis, and we are in the process now of evaluat-
ing the genetic influences. I would point out that lipopro-
tein (a) is elevated in only 40% of our patients, so it clear-
ly does not account for all of the risk involved.
Relating to your questions on antiphospholipid syn-
drome and hypercoaguable states, I certainly agree that
the precise impact of hypercoaguable states on premature
PAD has not been completely worked out. As you know,
the problems are related to the fact that these are acute
phase reactants. Many of these patients come back with
gangrene, tissue loss, or other acute conditions that render
the assays inaccurate.
All the patients in this study were screened at an ideal
time: specifically, serum assays were determined in each
patient when all the incisions were healed, there had been
no recent atherosclerotic events, such as myocardial infarc-
tion, and there was no gangrene or tissue loss. Rescreening
presented logistic problems because most of our patients
had multiple recurrences. Because most of these patients
were in a recurrent acute phase, the assays could not be
retested.
The original study that was published 2 years ago
showed that young white males with premature PAD had
a slightly higher prevalence of antiphospholipid antibodies,
as compared with controls, that was of borderline signifi-
cance. There was really no significant difference in the
prevalence of protein C protein or antithrombin III defi-
ciencies between the two groups. The present data suggest
that the antiphospholipid syndrome did not confer a risk
for progression of patients with premature peripheral vas-
cular disease. Some individuals may benefit from chronic
anticoagulation because of an antiphospholipid problem,
but this would necessitate a randomized prospective study
of a large population of patients to work out.
In terms of recommendations, we were disappointed
that we were unable to find any controllable risk factors
for progression. On the basis of the present data, we cur-
rently recommend waiting as long as possible to intervene
in these patients. We generally recommend revasculariza-
tion for limb preservation, not for claudication symptoms.
However, we concede that some young patients with
severe claudication may have long-term benefit from inter-
vention. Although there are no absolute predictors that
will help in the decision, we have previously shown that
young men and women with small aortas are predisposed
to aortofemoral graft failure.
There is no reason at the present time to screen for
hypercoaguable states, homocystine levels, or lipoprotein
(a) because we are not sure which patients would benefit
from treatment. We do recommend, of course, controlling
conventional risk factors, especially smoking, which prob-
ably increased the risk of coronary artery disease and cere-
bral vascular disease, and therefore may have an important
impact on the late survival of these patients.
